Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

NEUROHEALTH · Transitioning Psychotropic Alkaloids From Plants And Mushrooms To Neuroprotective Agents: Incorporating Computational Tools For The Development Of Novel Therapeutics

HORIZONStatus: SIGNED1 October 202530 September 2029EU funding €1,803,600Call HORIZON-MSCA-2024-SE-01

The NeuroHEALTH project aims to address the growing challenge of neurodegenerative diseases, such as Alzheimer's and Parkinson's, which affect millions worldwide and impose significant social and economic burdens. The project will harness the potential of neglected natural products (NPs), like alkaloids, from psychotropic plants and mushrooms that till recently had regulatory constrains. The integration of state of the art phytochemical analysis, with advanced computational tools will accelerate the discovery of novel NPs. In vitro and in vivo testing assays including zebrafish models will evaluate the safety and efficacy to reveal compounds of interest, that can enhance cognitive health and improve quality of life. Bioactive extracts and NPs will be scaled up and formulated in combination with a market analysis, sustainability and intellectual properties assessment will ensure that findings are relevant and applicable. Through strategic secondments and staff exchanges among academic and industry partners, NeuroHEALTH will foster interdisciplinary collaboration, enhancing knowledge transfer and innovation. Workshops, conferences, and outreach activities will engage diverse stakeholders, including professionals, policymakers, and the general public, promoting awareness of the project's findings and their implications for health care. By bridging the gap between traditional knowledge and modern science, NeuroHEALTH aims to deliver impactful solutions for neurodegenerative diseases, ultimately contributing to healthier aging populations. This timely initiative not only addresses urgent societal needs but also positions Europe at the forefront of innovative research in natural product-based therapeutics.

Consortium · 10 organisations

coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

EL · €320,640

participant

EDEX - EDUCATIONAL EXCELLENCE CORPORATION LIMITED

CY · €220,440

participant

NOVAMECHANICS LIMITED

CY · €180,360

participant

Galen-N

BG · €120,240

participant

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

EL · €210,420

participant

PARALAB-EQUIPAMENTOS INDUSTRIAIS E DE LABORATORIO S.A.

PT · €120,240

participant

NIKOLAOS A. FIKIORIS KAI SIA ETAIREIA PERIORISMENIS EFTHYNIS

EL · €120,240

participant

UNIWERSYTET MEDYCZNY W LUBLINIE

PL · €210,420

participant

FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA

ES · €120,240

participant

UNIVERSITE PARIS CITE

FR · €180,360

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.